Cite
Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma.
MLA
Kröger, Nicolaus, et al. “Comparison between Antithymocyte Globulin and Alemtuzumab and the Possible Impact of KIR-Ligand Mismatch after Dose-Reduced Conditioning and Unrelated Stem Cell Transplantation in Patients with Multiple Myeloma.” British Journal of Haematology, vol. 129, no. 5, June 2005, pp. 631–43. EBSCOhost, https://doi.org/10.1111/j.1365-2141.2005.05513.x.
APA
Kröger, N., Shaw, B., Iacobelli, S., Zabelina, T., Peggs, K., Shimoni, A., Nagler, A., Binder, T., Eiermann, T., Madrigal, A., Schwerdtfeger, R., Kiehl, M., Sayer, H. G., x00F6, rg#Beyer, J., Bornhäuser, M., Ayuk, F., Zander, A. R., & Marks, D. I. (2005). Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma. British Journal of Haematology, 129(5), 631–643. https://doi.org/10.1111/j.1365-2141.2005.05513.x
Chicago
Kröger, Nicolaus, Bronwen Shaw, Simona Iacobelli, Tatjana Zabelina, Karl Peggs, Avichai Shimoni, Arnon Nagler, et al. 2005. “Comparison between Antithymocyte Globulin and Alemtuzumab and the Possible Impact of KIR-Ligand Mismatch after Dose-Reduced Conditioning and Unrelated Stem Cell Transplantation in Patients with Multiple Myeloma.” British Journal of Haematology 129 (5): 631–43. doi:10.1111/j.1365-2141.2005.05513.x.